How to Help Your Patients Find Stelara in Stock: A Provider's Guide

In 2026, helping patients access ustekinumab requires more than writing a prescription — it involves navigating specialty pharmacy networks, insurance formularies, prior authorization pipelines, and an evolving biosimilar landscape. This guide is designed for dermatologists, rheumatologists, gastroenterologists, and other providers who want to reduce the time their patients spend without medication.

Step 1: Verify the Patient's Formulary Before Prescribing

The single most important step you can take is to verify which ustekinumab product is covered on the patient's insurance plan before the prescription is written. In 2026, most commercial payers have dropped brand-name Stelara from preferred formulary positions in favor of specific biosimilars — and which biosimilar is preferred varies significantly by PBM:

Optum Rx/UnitedHealth: Prefers Wezlana (ustekinumab-auub), available exclusively through Optum Specialty Pharmacy

Express Scripts/Cigna: Has dropped brand Stelara from its 2026 formulary in favor of biosimilar alternatives (check formulary for current preferred product)

Navitus: Prefers unbranded ustekinumab-aekn and other biosimilars over brand Stelara

Most electronic health record (EHR) systems now have formulary checking built in. Use it. If it's not available, ask a member of your care team to call the plan's provider line or check the payer's online formulary directly.

Step 2: Write the Prescription to Match the Plan's Covered Product

Once you know which ustekinumab product is on the patient's formulary, write the prescription to match. In general:

For interchangeable biosimilars (Wezlana, Pyzchiva, Yesintek, Selarsdi, Steqeyma, Otulfi, Starjemza): Writing "ustekinumab" or "Stelara" may allow pharmacy substitution to the formulary-preferred product, but this can cause delays. Writing the specific biosimilar by brand name is faster and cleaner.

For Imuldosa (ustekinumab-srlf): This is the only ustekinumab biosimilar without interchangeability designation. It must be specifically named on the prescription — it cannot be dispensed in place of Stelara based on a generic prescription.

Step 3: Submit Prior Authorization Promptly and Completely

Prior authorization is required for virtually every ustekinumab prescription. Many plans also require step therapy documentation showing that the patient has tried (and failed) one or more conventional therapies or other biologics. A complete, well-documented PA submission reduces delays and denials:

Include diagnosis codes, disease severity scores (PASI for psoriasis, CDAI for Crohn's, Mayo score for UC), and duration of disease.

Document all prior therapies tried, including conventional agents (methotrexate, cyclosporine, azathioprine) and any prior biologics.

Note any contraindications to alternatives the payer might suggest (e.g., active TB history, history of demyelinating disease, etc.).

Include TB test result and any other required pre-treatment screening documentation.

Step 4: Route to the Correct Specialty Pharmacy

Send the prescription to the specialty pharmacy that is in-network for the patient's plan and that carries the covered ustekinumab product. Routing to the wrong pharmacy — even one that stocks ustekinumab — can result in coverage denials and delays.

Many hub services (Janssen CarePath for brand Stelara; manufacturer hubs for biosimilars) can help route prescriptions to the appropriate specialty pharmacy. Enrollment in these hub services at the start of treatment simplifies the logistics for refills.

Step 5: Enroll Patients in Manufacturer Support Programs

Nearly all ustekinumab products have manufacturer-sponsored patient support programs:

Brand Stelara — Janssen CarePath (StelarawithMe): Copay reduction ($5/dose for eligible commercially insured patients), bridge supply for PA delays, and patient assistance for uninsured patients. Phone: 877-227-3728. Not valid for Medicare/Medicaid.

Biosimilar $0 copay programs: All seven biosimilar manufacturers offer $0 copay cards for commercially insured patients. Point patients toward the manufacturer's website or have your office staff enroll them at the time of PA submission.

Step 6: Use medfinder When Patients Can't Locate Their Medication

When a patient's specialty pharmacy doesn't have their ustekinumab in stock, or when the prescription has been routed to the wrong network, medfinder can help. medfinder contacts pharmacies in the patient's area to find which ones can fill the prescription, and texts results to the patient. This eliminates the hours patients and staff spend calling pharmacies one by one.

Managing Patients Transitioning from Brand Stelara to Biosimilars

When a patient's insurance forces a switch from brand Stelara to a biosimilar, reassure them that the change does not affect the medication's effectiveness. All seven interchangeable biosimilars have demonstrated comparable efficacy, safety, and immunogenicity to reference Stelara. Monitor patients for any changes in disease control after switching, per standard practice, though clinical data do not support expectation of a difference.

For a broader overview of the Stelara/ustekinumab market in 2026, see: Stelara Shortage: What Providers and Prescribers Need to Know in 2026